E-learningNews & eventsSpeakersPartners
Sign in
Sign in
Social media
Main pages
  • News & events
  • Speakers
  • Partners
  • Reviews
E-learning
  • Courses
  • Lectures
Corporate website
  • Sona Group

Contacts

  • info@sona-pharm.eu
  • Business days 9:00-17:00 EET
  • +372 505 9699
  • Ahtri 6, Tallinn, 10151, Estonia

Sona Group unites a network of independent pharmaceutical and healthcare companies operating in research, manufacturing and continued medical education.

This website is intended for informational and corporate communication purposes only and is not a substitute for medical advice.

© 2026 Sona Academy®. All rights reserved.

··Site map
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Legal Notice
  • Professional Medical Disclaimer
  • Data Collection and Privacy Disclaimer
  1. Home
  2. /
  3. All courses
  4. /
  5. LH as the key to ART success.
  6. /
  7. LH Deficiency in Patients of Advanced Reproductive Age: Pathogenesis and Treatment
Reproductive healthLecture

LH Deficiency in Patients of Advanced Reproductive Age: Pathogenesis and Treatment

An 18-oocyte cycle at 40 with a poor maturation rate is no longer surprising. Why advanced reproductive age is not only quantity but quality, what relative LH deficiency does to oocyte competence, and how to read the LH:FSH ratio when planning a stimulation in the over-38 patient.

Myroslava Vatsyk
Myroslava Vatsyk
Audio: UASubtitles: EN · UA · RU29 min
Myroslava Vatsyk

Myroslava Vatsyk

MD, PhD

Candidate of Medical Sciences (PhD), obstetrician-gynecologist and specialist in reproductive medicine at the «Mother and Child» Medical Center in Kyiv.

Ukraine

What was shown

The advanced reproductive age patient is not only a quantity problem — many present with reasonable antral follicle count, retrieve a normal number of oocytes, and still end the cycle with poor maturation and no euploid embryo. The talk reframes that picture as relative LH deficiency: the LH:FSH ratio drifts below 1 in the older patient, and the oocyte loses its competence support.

Key findings

Relative LH deficiency in patients over 38 affects oocyte quality more reliably than total oocyte yield. A high FSH dose without adequate LH support produces a paradoxical drop in mature-oocyte yield. The two-cell two-gonadotrophin model is most exposed at this age — theca-androgen supply, granulosa-aromatase activity and mitochondrial competence all depend on intact LH signalling.

What this means in practice

Measure LH and FSH on day 2-3 and compute the ratio. In patients 38+ with a low LH:FSH ratio, add recombinant LH or HMG to the protocol. Do not chase higher FSH alone in the older patient with a normal antral follicle count and a previous low-maturation cycle — the answer is in LH, not in dose.

Caveats

LH activity from HMG and recombinant LH is not pharmacokinetically identical; choice depends on patient and protocol. Mitochondrial decline with age sets a ceiling that no protocol fully escapes. Personalisation needs a previous cycle as anchor data.

Topics covered

  • LH:FSH ratio in age decline
  • Oocyte quality vs quantity
  • Relative LH deficiency
  • Stimulation protocols at 38+
  • AMH vs antral follicle count
  • Mitochondrial competence and steroidogenesis
Course

LH as the key to ART success.

View course

Related lectures

  • Personalizing LH supplementation in female infertility: which patients may benefitLH in reproductive medicine: personalized approaches in female and male infertility.
  • Personalizing gonadotropin treatment in male infertility: how APHRODITE may helpLH in reproductive medicine: personalized approaches in female and male infertility.
  • Why euploid embryos fail to implant?Why do euploid embryos fail to implant.
Myroslava Vatsyk

Myroslava Vatsyk

Candidate of Medical Sciences (PhD), obstetrician-gynecologist and specialist in reproductive medicine at the «Mother and Child» Medical Center in Kyiv.

Author of the lecture "LH Deficiency in Patients of Advanced Reproductive Age: Pathogenesis and Treatment"